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Abstract
Background: Errors, introduced through poor assessment of physical measurement or
because of inconsistent or inappropriate standard operating procedures for collecting,
processing, storing or analysing haematological and biochemistry analytes, have a nega-
tive impact on the power of association studies using the collected data. A dataset from
UK Biobank was used to evaluate the impact of pre-analytical variability on the power of
association studies.
Methods: First, we estimated the proportion of the variance in analyte concentration that
may be attributed to delay in processing using variance component analysis. Then, we
captured the proportion of heterogeneity between subjects that is due to variability in the
rate of degradation of analytes, by fitting a mixed model. Finally, we evaluated the im-
pact of delay in processing on the power of a nested case-control study using a power
calculator that we developed and which takes into account uncertainty in outcome and
explanatory variables measurements.
Results: The results showed that (i) the majority of the analytes investigated in our ana-
lysis, were stable over a period of 36h and (ii) some analytes were unstable and the
resulting pre-analytical variation substantially decreased the power of the study, under
the settings we investigated.
Conclusions: It is important to specify a limited delay in processing for analytes that are
very sensitive to delayed assay. If the rate of degradation of an analyte varies between
individuals, any delay introduces a bias which increases with increasing delay. If pre-
analytical variation occurring due to delays in sample processing is ignored, it affects
adversely the power of the studies that use the data.
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Introduction
A biobank may be defined as ‘an organized collection of
human biological material (e.g. blood, urine or extracted
DNA) and associated information stored for one or more
research purposes’.1,2 Most contemporary biobanks are
large by design because the aetiological determin-
ants(genes, environment and interactions) of complex dis-
eases are typically weak (e.g. relative risks between 1.1 and
1.3) and their resolution therefore demands many subjects3
with data that are both accurate and precise. Crucially,
errors introduced through poor assessment of physical
measurement or because of inconsistent or inappropriate
standard operating procedures (SOPs) for collecting, pro-
cessing, storing or analysing biosamples can seriously
impair data quality. This can dramatically reduce the stat-
istical power of a study, particularly if one is studying
gene-environment interactions.3,4 Given the vast cost and
effort that are needed to establish and maintain a contem-
porary biobank, even a small loss of power can impact
substantially on the balance of costs and benefits of de-
veloping adequately powered study resources. The quality
and future utility of biological samples can be affected by
factors arising during the collection, transport, processing
and storage of biosamples.5 It is therefore crucial to use
carefully selected and validated protocols that minimize
any changes in the quantity or nature of the constituents
(biological analytes) of each biosample and allow for the
further re-use of the samples.6–9 It is for this reason that
certain SOPs9,10 that ensure minimal pre-analytical vari-
ability between samples are published—as best practice
guidelines for biological resource centres—by organiza-
tions involved in the conceptualization, design and conduct
of sample collection, processing and analysis. This includes
guidelines from the National Cancer Institute (NCI),11
Organization for Economic Cooperation and Development
(OECD)12 and International Society for B, Environmental
R (ISBER),13 as catalogued in the website of the Public
Population Project in Genomics (P3G).14,15
A critical issue is the impact of any delay between sam-
ple collection and the processing step that definitively
stabilizes that sample (the ‘needle-to-freezer’ time). This is
because some biological analytes are not stable before per-
manent storage and their concentration changes over time.
For example, the concentration of aspartame transaminase
(AST), a biochemical analyte present in red blood cells,
increases by 15.2% at 21C and by 1.5% at 4C, over
24 h.16 If there is any tendency for an analyte to degrade,
or accumulate, over time ahead of stabilization, any delay
in definitive processing will introduce measurement error.
If the rate of degradation is very similar in all samples,
then an SOP requiring a fixed (though non-zero) delay till
processing (e.g. 24 h) will ensure that all samples to be ana-
lysed will be similarly affected and biostatistical and/or
epidemiological analyses may be unbiased. But if case and
control samples are processed under different protocols—
e.g. with a different needle-to-freezer time—serious sys-
tematic bias may arise. Additional problems will arise if
the rate of degradation varies markedly from subject to
subject. Then any delay in processing will introduce ran-
dom error that will reduce statistical power, even if every
sample is subject to the same delay. Furthermore, the mag-
nitude of the consequent bias will become steadily more
serious as the duration increases.
There are three possible solutions to pre-analytical vari-
ability in this setting: (i) use a common standard operating
procedure (SOP) involving local processing at all collection
sites; (ii) set up a large study with rapid sample transporta-
tion and central processing such that any delays are min-
imal; or (iii) carefully assess the impact of biosample
deterioration so that an evidence-based decision can be
made regarding the maximum delay that may be reason-
able and that, where possible, the delay time can be taken
into proper account in designing or analysing studies to be
based on the stored biosamples.
All else being equal, an SOP involving a short needle-to-
freezer time in all participants is undoubtedly to be pre-
ferred. But the first two solutions are both expensive. For ex-
ample, the first solution requires every collection site to have
a local capacity for state-of-the-art processing and storage,
rather than restricting such facilities to a single central facil-
ity. In a nationwide study this may well be unaffordable.
Given that any decisions about the optimum protocol will
therefore have major scientific and financial implications, it
is clear that a sound quantitative understanding is required
of the manner in which analytes degrade or accumulate in
unprocessed samples. But, because the degradation profile is
likely to vary from analyte to analyte, it is necessary to inves-
tigate a wide range of different biomarkers.
Key Messages
• This work demonstrates that between-subject heterogeneity in the stability of biological analytes can over time lead
to substantial degradation
• It also provides a framework for quantifying the power loss due to degradation.
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The analyses described in this article fulfil these aims.
They form part of the international biobank harmonization
programmes of P3G, Maelstrom17 and BioSHaRE-EU.18
The work is based on a set of pre-pilot blood samples that
were originally collected by UK Biobank with the express
purpose of exploring the stability of analytes in the period
prior to definitive storage. Although these data have previ-
ously been analysed19 with a closely related intention in
mind, the conclusions of those earlier analyses focused pri-
marily on the rate of degradation/accumulation per se,
rather than on the potential impact of heterogeneity in rate
among samples from different participants. As shall be dem-
onstrated, a comprehensive exploration of the latter raises
important additional considerations that ought to be taken
into proper account in developing the SOPs for sample col-
lection in a major biobank and/or in designing or analysing
the individual studies to be based upon a biobank.
Methods
Three complementary sets of analyses were undertaken,
exploring changes in the concentration of 47 analytes over
time in the period before definitive long-term storage. The
first set explored the extent to which any variation in the
measured concentration of each analyte might reasonably
be attributed to delays in processing. These replicated the
equivalent analyses reported in the earlier paper19 by
Jackson et al. and demonstrated that our approaches were
fundamentally equivalent. The second set focused specific-
ally on heterogeneity in the rate of change of concentration
of each analyte, between samples from different subjects.
The third set explored the impact of that heterogeneity on
the power of a typical association study. It is in the inter-
pretation of the second and third sets of analyses that our
investigation moves beyond that reported by Jackson
et al.19 and leads to important additional conclusions that
should necessarily be taken into account in considering the
power of association analyses to be based on a biobank.
Description of the data
UK Biobank (UKBB) is a large biobank of 500 000 partici-
pants, aimed at investigating the role of genetic factors, en-
vironmental exposures and lifestyle in the causes of major
diseases of late and middle age20. The data used in our ana-
lysis are from a pre-pilot study set up during the design
phase of UKBB. They consist of the measured values of 47
blood and urine analytes from 40 subjects, that were put
into definitive long-term frozen storage between 0 and 36 h
after initial blood collection. All samples were kept at 4C
until they were frozen. The 40 samples are from healthy
unrelated volunteers that were not among the 500 000
participants ultimately recruited into UK Biobank. The 40
volunteers consisted of 20 males with an average age of
56 years and a median of 56 years, and 20 females with an
average age of 51 years and a median of 49 years. In com-
parison, the UK biobank participants were from males and
females aged 40–69 years;21 the proportions of males and
females among the 500 000 UK Biobank participants are,
respectively, 45 and 55%.22 We do not have information
about the socio-economic statuses of the 40 subjects who
provided the samples analysed in this work.
The data structure is hierarchical, with three levels: sub-
ject; time point; and replicate measures. Analyte concentra-
tions were measured at four time points (0, 12, 24 and 36 h)
for 19 of the 47 analytes and at two time points (0 and 24 h)
for the other 28. The designated times represent time since
sample collection; 0 h implies the assay was carried out im-
mediately after sample collection (Figure 1). Two replicate
measurements were taken at each nominal time point except
at 24 h when four replicate measurements were taken: two
of those four were used to study the effect of freeze/thaw.19
These two latter samples were not true replicates and were
excluded from our analysis. A total of 320 measurement val-
ues were therefore analysed across the 40 participants for
each of the 19 analytes with measurement at four distinct
time points and 160 values in the other 28 analytes. The
analyte C Reactive Protein was excluded from the analysis
because its data were censored; all measurement values
<0.2 were reported as 0.2, and this distorted the correlation
structure both within and between subjects. The remaining
46 analytes were analysed one at a time.
First set of analyses: estimating the proportion of
the variance in analyte concentration that may
reasonably be attributed to delay in processing
The observed variability between different samples from
different participants reflects a combination of: (i) real bio-
logical heterogeneity between subjects; (ii) random meas-
urement error; and (iii) pre-analytic variability caused by
Figure 1. Repeated measurements are taken over 24 or 36h for each ana-
lyte and each subject. **Two assays only used in the present analysis.
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processing delays. It is the first of these that carries the infor-
mation driving useful scientific investigation. Although the
variability due to delay in processing is in fact a ‘real’ biolo-
gical effecti.e. the change in concentration (usually degrad-
ation) of a biological analyte over time isa real
phenomenon, its effect is to produce a loss of information
from the sample and, in that sense, is analogous to random
measurement error. To estimate the proportion of the
observed variability between subjects that can reasonably be
attributed to delay in processing, a three-level variance com-
ponent model (Figure 2) was fitted in MLwiN 2.1.23
This is a simple ‘random intercept’ model:
yijk ¼ b0ijkx0 Model 1
Where i, j and k, respectively, index observations at the rep-
licate measurement, processing time and subject levels of the
data hierarchy, x0 ¼ 1 and b0ijk ¼ ball þw0k þ v0jk þ e0ijk.
The terms w0k N 0,r2w0
 
, v0jk N 0,r2v0
 
and
e0ijk N 0,r2e0
 
are random ‘errors’acting at different levels
of the hierarchy. Variation at level 1 (r2e0) reflects random
measurement error. Variance at level 2 (r2v0) incorporates
variability arising from delay in processing. Level 3 is the
subject level and r2w0 therefore captures the real biological
difference between subjects that provides the basis of useful
scientific enquiry. The distributions of the residuals at levels
1, 2 and 3—e0ijk, v0jk and w0k—were explored and verified
as Gaussian using normal probability plots. The model was
fitted without explanatory variables; the ‘intercept’ covari-
ate, x0, took the constant value 1. The response of each ob-
servational unit (each sample in every subject) was therefore
modelled as having a common underlying expectation, ball.
Under the stated parameterisation, time was effectively
modelled as a non-ordered categorical variable. An ordinal
parameterization could instead have been used. This would
have been more powerful for detecting a weak but consist-
ent decline (or increase) in concentration over time. But,
for this part of the analysis, it was considered preferable to
minimize any assumptions and to treat each time point as
an independent entity rather than assuming a natural
order. Given that consistent changes over time were easily
detected for many of the analytes with four time points
anyway, it would appear that this decision was reasonable.
For analytes measured at only two time points, the non-
ordered and ordinal models are equivalent.
Second set of analyses: investigating
between-subject heterogeneity in the rate of
decline(or accumulation) of analytes
In considering the stability of a biological analyte over time,
it is helpful to recognize three fundamental possibilities
(Figure 3): (i) samples are stable and there is no change in the
concentration of the analyte over time; (ii) samples are un-
stable, but the rate of change in concentration is the same in
all samples from all individuals; and (iii) samples are unstable
and the rate of change in concentration varies from individ-
ual to individual. These three scenarios may be modelled
using a series of nested two-level multilevel models. Figure 4
depicts the model for analytes with two measurements at 0 h
and 24 h. For analytes with measurements at 0 h, 12 h, 24 h
and 36 h, there would be four additional boxes at level 1
(two replicate measures at each of 12 h and 36 h) and the
dummy time covariate is parameterized as indicated below.
Scenario 3 is the most general case. It is encapsulated in
the model 2 below:
yik ¼ b0ikx0 þ b1kx1ik Model 2
where i and k index individual measurements and different
subjects, respectively:
b0ik ¼ b0 þ u0k þ eik
b1k ¼ b1 þ u1k
x0 ¼ 1
x1ik ¼a dummy time covariate denoting the timing of the
ith measurement in the kth subject. This covariate is coded
Figure 3. Variation in biological analyte concentration over time;
changes in concentration of one analyte in four individuals are com-
pared in three different scenarios.
Figure 4. Graphical depiction of a two-level multilevel model for an ana-
lyte measured at two time points (0 and 24h) (model incorporates a
time covariate).
Figure 2. Graphical depiction of a three-level model fitted in MLwiN. 0h
and 24h components only for analytes measured twice (i.e. two
replicates).
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as 0 and 1 respectively for the time points 0 h and 24 h (for
analytes with two measurements); and as 0, 0.5, 1 and 1.5
respectively for the time points 0 h, 12 h, 24 h and 36 h (for
analytes with four measurements).
b0¼ expected concentration of analyte at time point 0 h;
b1¼ expected change in concentration of analyte between
time points 0 h and 24 h;
u0k N 0,r2u0
 
subject level random effect reflecting the
variance between subjects in the expected concentration
of the analyte at time point 0 h;
u1k N 0,r2u1
 
Ssubject level random effect reflecting the
variance between subjects in the expected rate of change
in concentration between time points 0 h and 24 h;
eik N 0,r2e
 
independent residual error terms at level 1.
Under the most general model (scenario 3), the expected
change in concentration between time points 0 h and 24 h
may be non-zero (b1= 0) and the rate of change may vary
from subject to subject (r2u1 > 0). Scenario 2 is a special
case of scenario 3, in which the slope may be non-zero
(b1=0) but the rate of change is the same in samples from
all subjects ðr2u1 ¼ 0). Scenario 1 is a special case of scen-
ario 2, in which the slope is identically zero in all subjects
(b1¼ 0 and r2u1 ¼ 0). Statistical inferences may be based on
a comparison of the likelihood of the nested models.
For example, a comparison of the likelihood between scen-
arios 3 and 2 enables inference on the question: ‘Is there
significant evidence of between-subject heterogeneity in
slope?’
The generality of model 2 may now be usefully ex-
tended to allow a correlation between u0k and u1k, re-
flected in an additional term (ru0:1Þ denoting the
covariance between the two sets of random effects. These
estimated variance and covariance terms might then be
used to estimate the overall variance at 0 h and the overall
variance at 24 h:
r20h ¼ r2u0 þ r2e Equation 1
r224h ¼ r2u0 þ 2ru0:1 þ r2u1 þ r2e Equation 2
All models used in undertaking the second set of analyses
were fitted using MLwiN23.
Third set of analyses: estimating the impact of
delays in sample processing on the power of
case-control studies
The second set of analyses (above) would appear to indi-
cate a straightforward way to address the scientific aims of
the third set of analyses. Our results for the second set of
analyses are similar to those of Jackson et al. who
concluded that the contribution of heterogeneity in slope
was negligible, and this supported their general conclusion
that ‘any instability in assay results up to 36 h is likely to
be small in comparison with between-individual differ-
ences and assay error’.
However, Jackson et al.’s ‘percentage of total variation
in assay measurements explained by between-individual
differences’ is a blunt tool. The between-individual vari-
ance at baseline (0 h) reflects the true biological signal of
interest. Any additional variance arising, after 0 h, from be-
tween-subject differences in slope, reflects a distortion of
that true signal. Furthermore, after baseline, the covariance
between the baseline biological signal and the subsequent
slope complicates the interpretation of the combined
‘between-individual variance’. This is because two add-
itional terms contribute to between-individual variance
after time 0: r2u1 and 2ru0:1 (Equations 1 and 2). If the co-
variance term ðru0:1Þ is negative, a higher analyte concen-
tration at baseline is, on average, associated with a steeper
subsequent decline. Lines depicting concentration (e.g.
Figure 5) may therefore converge from left to right but,
despite the resultant fall in total variability, the true biolo-
gical signal reflected in the magnitude of r2u0 neverthe-
less degrades as time progresses. Arguing quantitatively, if
ru0:1 is negative and greater in absolute magnitude
than r2u1=2, the total variance will decline, but the biolo-
gical signal will nevertheless degrade and statistical power
will fall.
One situation is particularly illuminating: if 2ru0:1 ¼
 r2u1, the total between-individual variance at time 0 and
time 1 (24 h) will be equivalent: r2u0 ¼ r2u0 þ 2ru0:1 þ r2u1, as
will the total variance r2u0 þ 2ru0:1 þ r2u1 þ r2e ¼ r2u0 þ r2e .
The proportion of total variability that is explained by vari-
ability between individuals—the parameter that Jackson
et al. compare over time—therefore remains constant, but
the original biological signal has degraded and is partially
balanced by variance arising from between-subject hetero-
geneity of slope. This latter may well be a real biological
difference between individuals, but it will not in general
be the same biological difference that accounts for
Figure 5. Using the variance components to determine total variability
at 0 and 24h.
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between-subject heterogeneity at baseline. Thus, although
Figure 2 in Jackson et al.19 does indeed demonstrate that
the proportion of total variance that can be explained by
variation between individuals is relatively constant over
time for most analytes, slope heterogeneity between indi-
viduals may nevertheless be causing a substantial degrad-
ation of the baseline biological signal and a loss of
statistical power. An alternative approach is therefore
needed to explore the degradation more rigorously: a dir-
ect comparison of statistical power with and without slope
heterogeneity between individuals.
To illustrate, let us consider perhaps the simplest of
scenarios: a nested case-control study is to focus on the
question: ‘Is the concentration of analyte A associated with
disease D?’ To explore statistical power, we might use the
ESPRESSO simulation-based power calculator (Estimating
Sample-size and Power in R by Exploring Simulated Study
Outcomes), that was originally developed to estimate
the power of nested case-control analyses based on
UK Biobank24 and has since been extended to model
quantitative exposures.25,26 The use of ESPRESSO to esti-
mate the power of case-control studies using uncondi-
tional logistic regression has been described in detail
elsewhere.3
Briefly, a simulation-based power calculation may be
undertaken involving a logistic regression model taking
case-control status (presence or absence of disease D) as its
binary outcome, one quantitative covariate reflecting the
analyte of interest A, and which has been ‘spiked’ by incor-
porating realistic levels of measurement error, and other
factors that are likely to influence statistical power
(see Appendix A, available as Supplementary data at IJE
online). The required sample size for a case-control ana-
lysis to have 80% power to detect the true association be-
tween D and A (across a range of true effect sizes) can then
be compared between two different settings. All simulation
parameters pertaining to the generation of AO, the
observed analyte concentration, in both settings for each
analyte are derived directly from the multilevel models fit-
ted earlier in the analysis.
Setting 1—no heterogeneity in degradation slope
All measurements are assumed to have been taken at 0 h
and slope heterogeneity has no impact. A vector of ‘true’
simulated analyte concentrations AT (error-free data) is
generated using a two-step procedure that separately gen-
erates the fixed expected values (AF) and random terms re-
flecting biological heterogeneity (AR). AT is generated with
a mean b0 (expected intercept at time 0 h) and a between-
subject variance of r2u0 (both estimated in the MLwiN
analysis for the chosen analyte—Table 2). The ‘observed’
analyte concentration AO is then obtained by adding a ran-
dom measurement error term (ER) to AT:
AF ¼ b0
AR  N 0, r2u0
 
AT ¼ AF þ AR
ER  N 0, r2e
 
AO ¼ AT þ ER
In this particular setting, the true biological signal associ-
ated with the analyte is captured by variation in AT and
the only error (measurement error)is reflected in ER: As in
any ESPRESSO analysis,3 AT is used to stochastically gen-
erate a vector of simulated ‘true’ case-control statuses
CCT, which are then subject to appropriate misclassifica-
tion error to generate an ‘observed’ case-control status vec-
tor CCO. A logistic regression of CCO on AO now allows
an estimation—based on this single simulation—of the
odds ratio (and standard error) relating CCO to a one unit
change in AO, and this in turn allows an empirical estimate
of the sample size that would have been required to detect
this effect with 80% power.3 This simulation process is
then repeated 500 times, and the estimated sample sizes
averaged to generate a consistent estimate of the required
sample size.3
Setting 2—slope heterogeneity present
All measurements are taken at 24 h. Precisely the same pro-
cedure is followed as in setting 1, except: (i) the fixed ef-
fects include b1, the overall slope, which is a fixed value in
the simulation and has no impact on power; (ii) the ran-
dom effects include SR which reflect slope heterogeneity;
(iii) the AR and SR random effects are generated so as to
have the correct covariance (ru0:1) (Equation 2) using
an approach we originally developed for simulating—
potentially negatively correlated—family data.27,28
Appendix B provides R code for generating the required
covariance (available as Supplementary data at IJE online).
AF ¼ b0 þ b1
AR  N 0, r2u0
 
AT ¼ AF þ AR
ER  N 0, r2e0
 
SR  N 0, r2u1
 
Crucially: Cov(AR, SR)¼ ru0:1
And finally: AO ¼ AT þER þ SR
It should be noted that SR, the random effects reflecting
slope heterogeneity, are actually multiplied by ‘time’ (see
model 2), but the parameterization is such that at 24 h
time¼ 1, so it is excluded from the presentation for
simplicity.
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Having estimated the sample sizes required in both
settings, their ratio (setting 2/setting 1) indicates the multi-
plicative increase in sample size that is required to precisely
compensate for slope heterogeneity if sample processing is
delayed to 24 h.
In order to render the power calculations for each ana-
lyte directly comparable, all distributional parameters—as
estimated in MLwiN—were first standardized by dividing
all the variance components for a given analyte by its esti-
mated r2u0, subtracting the mean (b0), and dividing b1
by
ffiffiffiffiffiffiffi
r2u0
q
. This meant that the estimated sample size pro-
vides 80% power to detect the true impact (as simulated)
of one standard deviation change on the odds of the par-
ticular disease being studied.
As usual,3 the ESPRESSO analyses incorporated a
full and realistic range of power-determining factors
(Appendix A, available as Supplementary data at IJE
online; see online material25,26 for a full list of parameter
values that were actually specified).
Results
First set of analyses
Using the three-level model with no heterogeneity in slope
between subjects (Model 1), the proportion of the observed
variability that can reasonably be attributed to delay in
processing time (r2v0) is 10% for 16 out of 46 analytes
(Table 1). Eight analytes have 5–10% of the observed vari-
ability attributable to delay in processing. For the remain-
ing 22 analytes, the contribution of the variance resulting
from delay in processing represents less than 5% of the
observed variance. Bicarbonate seems particularly sensitive
to delayed processing, with 61% of the observed variabil-
ity coming from r2v0.
Second set of analyses
Results are summarized in Table 2. Crucially by applying
the likelihood ratio test to Model 2 (Figure 2), a compari-
son under scenarios 2 (constant slope across individuals)
and 3 (heterogeneity of slope across individuals) indicates
that almost all analytes exhibited significant evidence of
between-person heterogeneity of slope. This finding is en-
tirely consistent with the equivalent finding reported by
Jackson et al.19 However, they concluded that despite the
statistical significance of this slope heterogeneity, it would
in practice have little impact on statistical power.
Third set of analyses
The quantitative impact of slope heterogeneity on estimated
sample size requirement is detailed in Table 3. Five analytes
demand the sample size to be more than doubled: bicarbon-
ate (2.32), albumin (2.27), total protein (2.21), basophils
(2.19) and magnesium (2.15). Three further analytes
required sample size inflation of at least 25% and, in total,
29 analytes demand an increase of at least 10%. As would
be anticipated, the loss of power, and hence the required in-
crease in sample size, is largest when r2u1 (the slope hetero-
geneity) is large relative to the biological signal (r2u0).
Discussion
Because of the complexity of the aetiological architecture
of complex diseases, and because individual causal effects
are often weak, statistical power is at a premium. This
implies a need for large sample sizes and measurements
that are both accurate and precise.3,29 Standard operating
procedures (SOPs) for biosample collection, processing,
storage and analysis must be explored in detail and chosen
with care. Furthermore, key decisions about SOPs that are
taken when a biobank or major epidemiological study is
first set up have an irrevocable impact on the future utility
of data and samples. They not only impact on the future
science to be based on a large-scale biobank, but also on
utility of the huge investment that societies and science pol-
icy makers are currently willing to make in creating and
managing biobanks. The particular set of SOPs that is
adopted by a biobank really matters.
The work reported in this paper builds directly on an
earlier paper by Jackson et al.19 Both papers use empirical
pre-pilot data collected by UK Biobank to explore one key
element of the SOP for biosample handling—the impact of
extending the needle-to-freezer time, i.e. the time delay be-
tween collecting a biosample (blood or urine) and putting
aliquots of that sample into definitive storage. Our paper
significantly extends the interpretation of one critical
parameter in the model: the impact of between-subject het-
erogeneity in the rate of degradation (decline or accumula-
tion) of each analyte studied. This extended interpretation
substantively changes the conclusions of the overall ana-
lysis, and must therefore be taken into account when
designing or using a biobank.
Our analyses and those undertaken in the earlier
paper19 can be directly compared; the mathematical mod-
els are equivalent and quantitative conclusions are effect-
ively the same. Thus, the estimated average percentage
change for each analyte over 12 h, the estimated probabil-
ity that a trend over time is truly negative and the likeli-
hood ratio test for heterogeneity are all very similar.
For example, Jackson et al.19 reported that the percentage
change in analyte concentration over 12 h of delay was
<3% in absolute magnitude for all but two analytes: insu-
lin (þ3.9%) and eosinophil count (12%). We entirely
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Table 1. Analytes ranked by decreasing contribution of delay in processing to observed variability between subjects. Two repli-
cate measurements where available for the analytes highlighted in light and four for the analyte highlighted in dark
Analyte (units) Mean Between
subject
variance (r2w0)
Variance
due to delay in
processing (r2v0)
Residual (r2e0) Proportion of
variance due to delay
in processing r2u0=r
2
v0 þ r2u0 þ r2e0
Bicarbonate (mmol/l) 26.094 0.679 1.288 0.156 61%
Albumin (g/l) 41.688 4.574 2.856 0.169 38%
Mean Corpuscular Haemoglobin
Concentration (g/dl)
33.016 0.144 0.112 0.058 36%
Total Protein (g/l) 68.731 14.459 9.181 2.406 35%
Potassium (mmol/l) 4.060 0.075 0.033 0.002 30%
Basophils (109) 0.045 0.000 0.000 0.000 28%
Eosinophils (109) 0.138 0.006 0.001 0.001 16%
Calcium (mmol/l) 2.235 0.007 0.001 0.000 15%
Packed Cell Volume (-) 0.421 0.002 0.000 0.000 15%
Haemoglobin (g/dl) 13.896 2.230 0.364 0.004 14%
Haemoglobin A1C (%) 3.305 0.051 0.011 0.017 14%
Sodium (mmol/l) 137.681 2.470 0.472 0.606 13%
Red Blood Cells (1012/l) 4.545 0.236 0.033 0.003 12%
Chloride (mmol/l) 106.325 3.882 0.550 0.388 11%
Platelet Count (109/l) 240.351 2873.890 346.155 46.660 11%
Haemoglobin A1CX (%) 0.484 0.004 0.000 0.000 10%
Glucose (mmol/l) 5.338 0.228 0.019 0.002 8%
Bilirubin (mmol/l) 14.786 16.922 1.491 2.274 7%
Glucose F Oxalate (mmol/l) 5.610 0.248 0.018 0.002 7%
Magnesium (mmol/l) 0.885 0.003 0.000 0.000 6%
Lymphocytes (109/l) 1.925 0.346 0.020 0.007 5%
Insulin (mIU/l) 7.240 17.508 0.942 0.049 5%
Cholesterol (mmol/;) 5.248 1.049 0.054 0.002 5%
Monocytes (109/l) 0.413 0.028 0.002 0.002 5%
Fibrinogen (g/l) 3.047 0.443 0.021 0.007 4%
High-Density Lipid (mmol/l) 1.567 0.189 0.007 0.002 3%
Amylase (IU/l) 71.525 559.694 15.512 2.038 3%
White Cell Count (109/l) 6.438 6.166 0.167 0.050 3%
Alkaline Phosphatase (IU/l) 61.395 307.281 7.483 2.499 2%
Creatinine (mmol/l) 89.838 160.505 3.894 14.900 2%
Mean Cell Volume (fl) 92.788 17.590 0.376 0.049 2%
Aspartate Aminotransferase (IU/l) 22.969 29.118 0.606 0.744 2%
Neutrophils (109/l) 3.918 4.505 0.068 0.027 1%
Mean Corpuscular Haemoglobin (pg) 30.627 1.599 0.023 0.046 1%
CK MB Fraction (IU/l) 4.795 21.852 0.235 0.146 1%
Urinary Urea (mmol/l) 246.229 11998.933 127.630 27.741 1%
Triglyceride (mmol/l) 1.265 0.556 0.006 0.001 1%
Creatinine Kinase (IU/l) 106.588 2655.407 20.775 2.013 1%
Gamma GT (IU/l) 30.596 354.594 2.142 3.012 1%
Alanine Aminotransferase (IU/l) 23.544 133.475 0.700 0.569 1%
Inorganic Phosphorus (mmol/l) 1.037 0.021 0.000 0.002 0%
Uric Acid (mmol/l) 301.956 3336.344 12.213 3.619 0%
Blood Urea Nitrogen (mmol/l) 2.688 0.319 0.001 0.002 0%
Urinary Calcium (mmol/l) 2.297 1.976 0.005 0.027 0%
Urinary Sodium (mmol/l) 96.128 2605.497 0.083 9.059 0%
Urinary Potassium (mmol/l) 49.653 651.427 0.657 6.833 0%
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Table 2. Heterogeneity in rate of change of analyte concentration (slope variance) and results of the comparison between the
models for scenario 3 and scenario 2 (i.e. 2-level model with and without a random slope). The analytes for which the models
were fitted with two time points are highlighted in light whereas those for which the models were fitted with four time points
are highlighted in dark
Analyte Mean (b0) Slope (b1) Expected %
change
per 12 h
Between-
subjects
variance (r2u0)
Between-
slopes
variance (r2u1)
Residual
(r2e0)
v2 slope
heterogeneity
P-Value
Bicarbonate 26.688 –1.188 –2.22 1.506 1.165 0.156 64.687 8.78E16
Albumin 42 –0.763 –0.91 6.766 5.131 0.169 151.673 7.47E35
Mean Corpuscular
Haemoglobin
Concentration
32.9 0.231 0.35 0.166 0.17 0.058 32.018 1.53E08
Total Protein 69.488 –1.513 –1.09 20.84 16.075 2.406 59.583 1.17E14
Potassium 4.1071 –0.0316 –0.77 0.0925 0.0072 0.0177 188.21 1.35E41
Basophils 0.046 –0.002 –2.47 0.00036 –0.00011 0.00008 31.491 2.00E08
Eosinophils 0.157 –0.039 –12.4 0.009 0.001 0.001 27.142 1.89E07
Calcium 2.2596 –0.0167 –0.74 0.0075 0.0001 0.0001 689.67 1.74E150
Packed Cell Volume 0.428 –0.014 –1.68 0.002 0.001 0.00002 142.267 8.50E33
Haemoglobin 14.078 –0.363 –1.29 2.482 0.597 0.004 270.89 7.26E61
Haemoglobin A1C 3.2614 0.0289 0.89 0.0566 0.0021 0.0225 113.64 2.11E25
Sodium 138.1313 –0.3000 –0.22 2.3641 0.0840 0.7621 0.00 1.00Eþ00
Red Blood Cells 4.604 –0.118 –1.29 0.259 0.052 0.003 118.8 1.16E27
Chloride 106.15 0.35 0.16 4.159 0.978 0.388 23.268 1.41E06
Platelet Count 245.738 –11.408 –2.32 3269.157 548.204 46.66 86.048 1.76E20
Haemoglobin A1CX 0.4859 –0.0011 –0.23 0.0036 0.0001 0.0005 704.40 1.10E153
Glucose 5.415 –0.021 –0.49 0.228 0.031 0.002 163.01 2.49E37
Bilirubin 15.225 –0.879 –2.89 18.188 2.21 2.274 6.519 1.07E2
Glucose F Oxalate 5.6505 –0.0270 –0.48 0.2530 0.0036 0.0108 224.60 1.69E49
Magnesium 0.888 –0.006 –0.32 0.003 0.0036 0.00005 59.021 1.56E14
Lymphocytes 1.966 –0.082 –2.09 0.389 0.032 0.007 45.793 1.31E11
Insulin 6.8372 0.2681 3.92 17.5932 0.2391 0.4166 0.00 1.00Eþ00
Cholesterol 5.4026 –0.1030 –1.91 1.1333 0.0044 0.0272 92.41 8.58E21
Monocytes 0.424 –0.022 –2.59 0.029 0.002 0.002 9.628 1.92E03
Fibrinogen 3.161 –0.159 –2.09 0.471 0.038 0.008 183.268 9.37E42
High-Density Lipid 1.6379 –0.0452 –2.76 0.2255 0.0010 0.0037 364.58 6.80E80
Amylase 73.051 –3.05 –2.09 599.198 21.722 2.038 85.765 2.03E20
White Cell Count 6.515 –0.155 –1.19 6.061 0.311 0.05 56.796 4.83E14
Alkaline Phosphatase 62.471 –2.146 –1.72 318.718 10.379 2.497 38.308 6.04E10
Creatinine 91.0225 –0.7900 –0.87 173.8155 0.4029 16.7704 0.00 1.00Eþ00
Mean Cell Volume 93.049 –0.521 –0.28 17.309 0.48 0.049 80.493 2.92E19
Aspartate
Aminotransferase
23.05 –0.163 –0.35 29.938 1.186 0.744 13.05 3.03E04
Neutrophils 3.923 –0.009 –0.11 4.313 0.136 0.027 49.6 1.89E12
Mean Corpuscular
Haemoglobin
30.603 0.049 0.08 1.621 0.044 0.046 6.294 1.21E02
CK MB Fraction 4.905 –0.218 –2.22 24.768 0.417 0.146 60.985 5.75E15
Urinary Urea 246.5983 –0.2461 –0.1 11609.8408 24.6165 101.8849 0.00 1.00Eþ00
Triglyceride 1.3075 –0.0281 –2.15 0.5835 0.0006 0.0038 414.34 1.07E90
Creatinine Kinase 108.225 –3.275 –1.51 2673.261 30.825 2.013 105.437 9.80E25
Gamma GT 31.3238 –0.4881 –1.56 389.5020 0.54040 3.7376 0.00 1.00Eþ00
Alanine Aminotransferase 23.788 –0.488 –1.02 135.898 1.162 0.569 18.373 1.82E05
Inorganic Phosphorus 1.042 –0.01 –0.46 0.021 0.0001 0.0016 0.275 6.00E01
Uric Acid 300.875 2.163 0.36 3328.925 19.749 3.619 49.927 1.60E12
Blood Urea Nitrogen 2.69 –0.004 –0.07 0.317 0.002 0.002 8.976 2.74E03
Urinary Calcium 2.3050 –0.0056 –0.24 1.9686 0.0044 0.0250 0.00 1.00Eþ00
Urinary Sodium 96.3476 –0.14630000 –0.15 2629.6777 0.5562 8.3056 0.00 1.00Eþ00
Urinary Potassium 50.00150 –0.23490 –0.47 686.52110 0.60450 6.43210 0.00 1.00Eþ00
International Journal of Epidemiology, 2014, Vol. 43, No. 5 1641
Downloaded from https://academic.oup.com/ije/article-abstract/43/5/1633/2949589
by University of Newcastle user
on 27 February 2018
concur, with corresponding estimates of þ3.92% and
12.4% for insulin and eosinophil count, respectively.
Where our interpretation departs from the Jackson
et al. paper,19 and our analyses and findings provide an
important complement to theirs, is in regard to the impact
of heterogeneity between individuals in the rate of degrad-
ation of a given analyte. On the basis of their Figure 2
(‘Percentage of total variation in assay measurements ex-
plained by between-individual differences, plotted against
time of measurement’), Jackson et al.19 concluded that any
such heterogeneity would have only a limited impact. This
contributed to a globally reassuring conclusion that ‘any
instability in assay results up to 36 h is likely to be small in
comparison with between-individual differences and assay
error’, and that ‘a single assay measurement at any time be-
tween 0 and 36 h should give a representative value of the
analyte concentration at time zero for that individual’.
In contrast, our extended analysis suggests that the situ-
ation is more complex. This is of direct relevance both to
selecting SOPs for biosample management in designing
and constructing a biobank, and to designing and choosing
the sample size of future studies that may use that biobank
as a platform for investigating causal pathways involving
biomarkers and complex diseases. Thus, our analyses sug-
gest that for five of the biomarkers we studied (more than
1 in 10), the loss of biological signal consequent upon
delayed processing for even 24 h would require at least a
doubling of the sample size of a case-control study to inves-
tigate the impact of that analyte on disease risk. More
broadly, our results suggest that between-subject hetero-
geneity in the stability of a significant number of key analy-
tes can, over 24 h, lead to substantive degradation in the
biological information in biosamples and a requirement to
increase power by at least 25% to compensate (Table 3).
This interpretation implies that—if such analytes are to be
explored in a study based on a biobank—there is a need to
take proper account of the processing delay in interpreting
the measured concentrations of those analytes, and to ap-
propriately increase the sample size of the study to counter
this loss of information.
An important general message is that the management
rigor, including forward planning and comprehensive
documentation, that is fundamental to setting up and ex-
ploiting a large scale biobank,15 is desirable in its own
right. Well-thought-through and well-documented SOPs,
appropriate ancillary data (e.g. recording just how long an
individual biosample was delayed before entering defini-
tive frozen storage) and formal tests of quality assurance
are all critical if we are to know where problems may arise
and can respond appropriately to them. Furthermore,
given that all good biobanks do implement a rigorous re-
gime for data and sample management, the larger the size
Table 3. Sample size increase required to compensate for
power loss caused by bias arising from slope heterogeneity.
The analytes for which the models were fitted with two time
points are highlighted in light whereas those for which the
models were fitted with four time points are highlighted in
dark
Analyte Multiplicative increase
required to compensate
for power loss
Bicarbonate 2.32
Albumin 2.27
Total Protein 2.21
Basophils 2.19
Magnesium 2.15
Mean Corpuscular Haemoglobin
Concentration
1.83
Haemoglobin 1.26
Packed Cell Volume 1.25
Chloride 1.23
Red Blood Cells 1.21
Platelet Count 1.18
Eosinophils 1.13
Bilirubin 1.13
Potassium 1.11
Monocytes 1.09
Lymphocytes 1.08
Haemoglobin A1C 1.06
White Cell Count 1.04
Aspartate Aminotransferase 1.04
Amylase 1.04
Haemoglobin A1CX 1.03
Alkaline Phosphatase 1.03
Neutrophils 1.03
Mean Corpuscular Haemoglobin 1.03
Sodium 1.02
Mean Cell Volume 1.02
Glucose (F Oxalate) 1.02
Glucose 1.02
Calcium 1.01
Insulin 1.01
Cholesterol 1.01
Fibrinogen 1.01
Creatinine 1.01
Alanine Aminotransferase 1.01
CK MB Fraction 1.01
Creatinine Kinase 1.01
Inorganic Phosphorus 1.01
High-Density Lipid 1.00
Triglyceride 1.00
Blood Urinary Nitrogen 1.00
Uric Acid 1.00
Urinary Urea 1.00
Urinary Calcium 1.00
Urinary Potassium 1.00
Urinary Sodium 1.00
Gamma GT 1.00
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of any given biobank the better, provided this does not im-
pinge on biosample quality. It is often impossible to avoid
combining scarce data from several studies together in
order to answer an important scientific question,3 but there
is an undoubted benefit in minimizing the number of dif-
ferent studies that must be combined—because this limits
the potential heterogeneity. Ultimately, one can do no
more than aim to work where possible with larger, well
designed biobanks/studies, and to use whatever ancillary
information may be available from each to try to control
for whatever heterogeneity may be unavoidable.
Large-scale biobanks—particularly those with a na-
tional or even supranational design —must carefully think
through their SOPs for obtaining, transporting and pro-
cessing biosamples. Given that some analytes do appear to
be particularly sensitive to a prolonged needle-freezer time,
and given that in some cases this is due to heterogeneity in
degradation slope, this delay should wherever possible be
minimized. However, immediate biosample processing at
point of collection can be very expensive; some delay is
therefore inevitable and an undesirably long delay may
sometimes be unavoidable. It is therefore universally desir-
able to record that delay, to provide those ancillary data
with the relevant biosamples and/or analyte concentration
estimates when they are released to researchers and to
ensure that the time course of pre-processing-related
degradation of commonly studied analytes is properly
understood.
Our study complements the findings of Jackson et al. in
identifying a number of analytes where the rate of degrad-
ation is unusually high. Particular care should be taken
in analysing data pertaining to such analytes if cases and
controls have been sourced from different studies with
different SOPs or if the delay times vary widely within an
individual study. In some circumstances, where one of
these analytes happens to be the primary focus of scientific
attention, and there is a desire to avoid having to adjust for
differing delay times, consideration maybe ought to be
given to delaying processing of all samples to a common,
achievable, goal. However, our analysis suggests that such
a plan may be counterproductive if the analyte happens to
be one of those where the heterogeneity of degradation
varies so much between samples that any delay can lead to
loss of power.
Finally, if an analyte of interest is known to be particu-
larly sensitive to processing delay—either because of
rapid degradation or because of marked heterogeneity of
degradation—full account must be taken in designing sub-
studies. Rather than trying to produce exhaustive lists of
power adjustments for different delay times for a wide
range of analytes, we are currently extending the
ESPRESSO power calculator to take data from studies
such as the biobank pre-pilot study analysed in this paper,
and to convert these data into sample size inflation figures
for different settings and analytes. Given that there are
now many more analytes that can reasonably be analysed
in a high throughput manner than there were when the UK
Biobank data that we analysed were collected, there is
a clear need to undertake equivalent studies for other
analytes and in other settings. For robustness, these studies
should be based on measurements at four time points for
all analytes rather than just two for some.
Although the data used in this project were generated
in a pre-pilot phase of UK Biobank, the nature of the
analysis is such that its conclusions should be generaliz-
able to other biobanks and large-scale biosample collec-
tions. Furthermore, although UK Biobank has now
completed its primary sample collection and its standard
operating protocols for that collection are therefore im-
mutable, the analysis we describe will be of value to UK
Biobank in future sample collection sweeps, and to poten-
tial users designing sub-studies to explore the effect of
biomarkers.
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